Residency · Residency · Child Adolescent Psychiatry

Separation Anxiety, Generalized Anxiety, and Social Anxiety in Children

Overview

Anxiety disorders are the most common psychiatric disorders in children, with a combined prevalence of approximately 15-20%. Three core pediatric anxiety disorders — separation anxiety disorder (SAD), generalized anxiety disorder (GAD), and social anxiety disorder (SoAD) — frequently co-occur and share overlapping treatment approaches. CBT is the gold-standard first-line treatment, with the Coping Cat program being the most extensively studied manualized protocol. Pharmacotherapy with SSRIs is indicated for moderate-to-severe presentations or when CBT alone is insufficient. The landmark CAMS (Child/Adolescent Anxiety Multimodal Study) established that combination treatment with CBT plus sertraline is the most effective approach, achieving an 81% response rate.

Normative Fears vs. Clinical Anxiety

Fears are developmentally normal and follow a predictable trajectory across childhood. Infants fear loud noises and strangers. Toddlers fear separation from caregivers, the dark, and animals. Preschool-age children fear imaginary creatures, thunder, and being alone. School-age children worry about injury, death, natural disasters, and social evaluation. Adolescents become concerned about social humiliation, academic failure, and existential issues.

Separation Anxiety Disorder

Presentation

Separation anxiety disorder involves excessive anxiety about separation from attachment figures that goes beyond what is expected for the child's developmental level. Children with SAD worry about harm befalling their attachment figures or about events that might cause separation — kidnapping, getting lost, accidents. They show reluctance or outright refusal to go to school, attend sleepovers, or participate in activities that require separation. Difficulty sleeping alone and nightmares with separation themes are common. Physical complaints such as stomachaches, headaches, and nausea frequently emerge when separation is anticipated. Clinging behavior and shadowing parents around the house are characteristic. The peak age of onset is 7-9 years, and the prevalence is approximately 4%.

Developmental Considerations

Separation anxiety is normative in toddlers, peaking around 12-18 months, and typically resolves by age 3-4. Clinical SAD is diagnosed when symptoms persist or emerge beyond this normative developmental window and cause significant impairment. SAD is the most common anxiety disorder in children under age 12. Longitudinal data suggest that SAD in childhood may be a developmental precursor to panic disorder in adulthood.

Generalized Anxiety Disorder

Presentation

Children with GAD display excessive, difficult-to-control worry across multiple domains — academic performance, health, safety, world events, punctuality, and peer approval. They are often described as "little worrywarts" or "miniature adults" who seek excessive reassurance, are perfectionistic, and worry about matters beyond their developmental level. Physical symptoms include muscle tension, restlessness, fatigue, difficulty concentrating, sleep disturbance, and gastrointestinal symptoms. These children often have difficulty making decisions due to fear of making the wrong choice, and their reassurance-seeking is repetitive and never fully satisfying.

Developmental Considerations

While GAD can be diagnosed in children, it is more commonly identified in late childhood and adolescence. Younger children may express worry primarily through somatic complaints and behavioral avoidance. Perfectionism and excessive self-criticism are common features. GAD in children frequently co-occurs with SAD and SoAD.

Social Anxiety Disorder

Presentation

Social anxiety disorder involves a marked fear of social situations in which the child is exposed to scrutiny by others, with fear of negative evaluation, embarrassment, humiliation, or rejection. In children, this anxiety must occur in peer settings, not exclusively with adults. Avoidance may extend to speaking in class, performing, eating in public, using public restrooms, initiating conversations, and attending parties. While SoAD may present as extreme shyness, it goes beyond temperamental shyness in both severity and functional impairment. Physical symptoms include blushing, trembling, nausea, sweating, and freezing or going blank. The condition may be misidentified as oppositional behavior when the child refuses to participate. Prevalence is approximately 5-10% of adolescents.

Developmental Considerations

Stranger anxiety (6-12 months) and social wariness (2-3 years) are normative precursors that most children outgrow. SoAD typically emerges in late childhood or early adolescence as social awareness increases. Behavioral inhibition — a temperamental trait characterized by wariness with novel stimuli — is the strongest early predictor of SoAD. SoAD is closely associated with selective mutism, which is often considered a severe variant of social anxiety.

Assessment

Clinical Interview

The gold-standard diagnostic interview for pediatric anxiety is the ADIS-C/P (Anxiety Disorders Interview Schedule for Children/Parents), a structured or semi-structured interview. The child and parent should be interviewed separately, as children may minimize symptoms out of embarrassment or maximize them when seeking reassurance. Functional impairment should be assessed across domains including school attendance, academic performance, peer relationships, family activities, and sleep. Clinicians should specifically screen for avoidance behaviors that families may not label as "anxiety."

Rating Scales

Several validated rating scales support clinical assessment. The SCARED (Screen for Child Anxiety Related Disorders) is a free, 41-item parent and child self-report measure with subscales for SAD, GAD, SoAD, panic, and school avoidance. The MASC-2 (Multidimensional Anxiety Scale for Children) is a comprehensive self-report measure. The Spence Children's Anxiety Scale is free and available in multiple languages. The CGI-S and CGI-I provide clinician-rated global severity and improvement ratings.

Evidence-Based Treatment

Cognitive Behavioral Therapy (First-Line)

CBT is the most evidence-based psychotherapy for pediatric anxiety disorders. Its key components include psychoeducation, somatic management through relaxation training, cognitive restructuring, graduated exposure, and relapse prevention. Among these, exposure — systematic, gradual confrontation of feared situations — is the most critical therapeutic element.

Coping Cat Program (Kendall)

The Coping Cat program is the most extensively studied CBT manual for childhood anxiety, designed for ages 7-13. It consists of 16 sessions organized in two phases. Phase 1 (sessions 1-8) covers psychoeducation, identifying anxious feelings and thoughts, and developing a coping plan known as the FEAR plan: Feeling Frightened? Expecting bad things? Actions and Attitudes that can help, and Results and Rewards. Phase 2 (sessions 9-16) involves graduated in-vivo exposure to feared situations using the FEAR plan. Randomized controlled trial evidence shows that approximately 60% of treated children are diagnosis-free at post-treatment compared to approximately 15% with waitlist, and these effects are maintained at seven-year follow-up. The C.A.T. Project is the adolescent adaptation of Coping Cat for ages 14-17.

Other CBT Programs

Other effective programs include Cool Kids (an Australian group CBT program), the FRIENDS program (a group-based intervention that can be delivered in school settings), and brief eight-session CBT versions that have shown effectiveness for some children.

Pharmacotherapy

SSRIs

SSRIs are the first-line pharmacotherapy when CBT alone is insufficient or for moderate-to-severe anxiety. Fluoxetine, fluvoxamine, and sertraline have the most evidence for pediatric anxiety. Fluvoxamine was the first SSRI to demonstrate efficacy in pediatric anxiety in the landmark RUPP Anxiety Study (2001) for ages 6-17. Sertraline was the SSRI used in the CAMS study and has demonstrated effectiveness across SAD, GAD, and SoAD. Dosing should start low (for example, sertraline 12.5-25 mg or fluoxetine 5-10 mg) with gradual titration. Response typically takes 4-8 weeks, and an adequate trial requires 8 weeks at a therapeutic dose. Common side effects include GI upset, headache, activation or restlessness, and sleep changes. The FDA black box warning applies, though suicidal ideation is rare in anxiety trials compared to depression trials.

SNRIs

Duloxetine is FDA-approved for GAD in children ages 7 and older (as of 2014). Venlafaxine has some supporting evidence but carries more side effects and is harder to discontinue. SNRIs are generally considered second-line after SSRI failure.

The CAMS Study (Child/Adolescent Anxiety Multimodal Study)

The CAMS study was a landmark NIMH-funded RCT enrolling 488 children ages 7-17 with SAD, GAD, or SoAD. Participants were randomized to four arms: sertraline, CBT, combination (sertraline plus CBT), or placebo. At 12 weeks, combination treatment achieved an 81% response rate, significantly superior to all other treatments. CBT alone achieved a 60% response rate, sertraline alone achieved 55%, and placebo achieved 24%. All active treatments were superior to placebo, and combination treatment was superior to either monotherapy. Long-term follow-up showed sustained benefits, though some relapse occurred.

When to Add Pharmacotherapy

Pharmacotherapy should be considered when anxiety is moderate-to-severe and significantly interferes with functioning, when CBT alone has been inadequate after 8-12 weeks, when the child is unable or unwilling to engage in exposure-based CBT, when comorbid depression is present (especially if moderate-to-severe), when the family prefers medication after an informed discussion, or when access to CBT is limited and medication may be more readily available.

<image>A treatment algorithm for pediatric anxiety disorders (SAD, GAD, SoAD) based on CAMS data. Start with severity assessment: mild (CBT monotherapy as first-line), moderate-to-severe (combination CBT + SSRI as first-line per CAMS). If CBT alone is used and inadequate after 8-12 weeks, add SSRI. If SSRI alone is used and inadequate, add CBT or switch SSRI. Show response rates from CAMS at each treatment step: combination 81%, CBT 60%, sertraline 55%, placebo 24%.</image>

<image>An infographic comparing the three core pediatric anxiety disorders: Separation Anxiety Disorder, Generalized Anxiety Disorder, and Social Anxiety Disorder. For each disorder, show: typical age of onset, core fear, common presenting symptoms, developmental precursors (normative fears), and key functional impairments. Include a Venn diagram in the center showing the high rates of comorbidity among the three disorders.</image>

<image>A visual overview of the Coping Cat FEAR Plan. Show four steps in a staircase format: F (Feeling frightened? -- identify anxious body sensations), E (Expecting bad things to happen? -- identify anxious thoughts), A (Actions and Attitudes that can help -- coping strategies, relaxation), R (Results and Rewards -- evaluate outcome, reward brave behavior). Include an exposure hierarchy example on the side showing graduated steps from least to most anxiety-provoking situations.</image>

Clinical Pearls

Anxiety disorders are the most common psychiatric disorders in children, yet they are frequently underdiagnosed because children may not report internal distress and avoidance may be accommodated by families without being recognized as pathological. The CAMS study established that combination treatment (CBT plus sertraline) is the most effective approach, achieving an 81% response rate. Exposure is the most critical component of CBT for anxiety; avoidance maintains and worsens anxiety, and any treatment that does not address avoidance will be incomplete. Separation anxiety is the most common anxiety disorder in children under 12 and may serve as a developmental precursor to adult panic disorder. Behavioral inhibition in toddlers is the strongest temperamental predictor of later social anxiety disorder. Family accommodation — modifying family routines to reduce the child's anxiety — maintains the anxiety and should be identified and addressed as a treatment target. SSRIs are effective and generally well tolerated for pediatric anxiety, with lower rates of suicidality-related adverse events in anxiety trials than in depression trials. School refusal is often a manifestation of anxiety, usually SAD or SoAD, and requires prompt intervention to prevent entrenchment.

References

• Walkup, J.T. et al. (2008). Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety (CAMS). NEJM, 359(26), 2753-2766.
• Kendall, P.C. (1994). Treating anxiety disorders in children: results of a randomized clinical trial. JCCP, 62(1), 100-110.
• RUPP Anxiety Study Group. (2001). Fluvoxamine for the treatment of anxiety disorders in children and adolescents. NEJM, 344(17), 1279-1285.
• Kendall, P.C. et al. (2004). Coping Cat Workbook (2nd ed.). Ardmore, PA: Workbook Publishing.
• Beesdo, K. et al. (2009). Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatric Clinics of North America, 32(3), 483-524.
• Birmaher, B. et al. (1997). Childhood and adolescent anxiety disorders: a review. JAACAP, 36(7), 918-932.

Read this lecture as Markdown